NEOBKhODIMOST' I BEZOPASNOST' KOMBINIROVANNOY LEKARSTVENNOY TERAPII PATsIENTOV S NARUShENIYaMI MOChEISPUSKANIYa


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Full Text

Restricted Access

References

  1. Djavan B., Fong Y.K., Harik M. et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004; 64: 1144-1148.
  2. Irwin D.E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006; 50:1306-1315.
  3. Sexton C.C., Coyne K.C., Kop Z.S. et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009; 103 (Suppl 3): 12-23.
  4. Kirby R., Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Wein A.J., Kavoussi L.R., Novick A.C. eds. Campbell-Walsh Urology. 9th ed. New York: Elsevier; 2007: 2766-2782.
  5. Clark R.V., Hermann D.J., Cunningham G.R. et al. Marjed suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J. Clin. Endocrinol. Metab. 2004; 89:2179-2184.
  6. Lepor H. The evolution of alphq-blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 2006; 8 (Suppl 4): S3-S9.
  7. Montorsi F., Roehrborn C., Garcia-Penit J. et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int. 2011;107(9):1426—1431.
  8. Chapple C. R., Roehrborn C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract in men: focus on the bladder. Eur. Urol. 2006; 49: 651-659.
  9. Hyman M. J., Groutz A., Blaivas J. G. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. 2001; 166:550-552.
  10. Knutson T., Edlund C., Fall M., Dahlstrand C. BPH with coexisting overactive bladder dysfunction - an everyday urological dilemma. Neurourol Urodyn 2001; 20:237-247.
  11. Abdel-Aziz K. F., Lemack G. E. Overactive bladder, outlet, or both? Curr. Urol. Rep. 2002; 3:445-451.
  12. Andersson K. E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004; 3:46-53.
  13. Chapple C., Khullar V., Gabriel Z. et al. The effects of antimuscarinic treatments in overactive bladder: a systematic review and metaanalysis. Eur. Urol. 2005; 48:5-26.
  14. Kaplan S. A., Walmsley K., Te A. E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J. Urol. 2005; 174: 2273-2276.
  15. Abrams P., Kaplan S. A., De Koning Gans H.J. et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 2006; 175:999-1004.
  16. Roehborn C. G., Abrams P., Rovner E. S. et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006; 97:1003-1006.
  17. Lee J. Y., Kim H. W., Koh J. S. et al. Comparisonof doxazosin with or without tolterodine in men with symptomatic baldder outlet obstruction and an overactive bladder. BJU Int. 2004; 94: 817-820.
  18. Athanasopoulos A., Gyftopoulos K., Giannitsas K. et al. Combination treatment with an alfa-blocker plus an anticolinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J. Urol. 2003; 169: 2253-2256.
  19. Kaplan S. A., Roehrborn C. G., Rovner E. S. et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319-2328.
  20. Chapple C., Herscham S., Abrams P. et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur. Urol. 2009; 56:534-541.
  21. Sussman D. O., Kraus S. R., Carlsson M. et al. Onset of efficacy of tolterodine extendedrelease in patients with overactive bladder. Curr. Med. Res. Opin. 2007; 23: 777-781.
  22. McNaughton-Collins M., Barry M. J. Managing patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Am. J. Med. 2005;118(12):1331-1339.
  23. Hong W.S., Chung H., Lee J.M. et al. Polypharmacy and centralnervous system adverse effects of anticholinergic agents in the men with benign prostatic hyperplasia. J. Korean Continence Soc. 2007; 11:24-29.
  24. Abrams P., Chapple C., Knoury S. et al. Evaluation and treatment of lower urinary tract symptoms in older men. J. Urol. 2009; 181:1779-1787.
  25. Chapple C. et al. Systematic review of therapy of men with overactive bladder. Can. Urol. Asssoc. J. 2011; 5 (Suppl. 2):143-145.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies